Vaccine Maitri: Modi’s Decision to Export COVID Vaccines Globally

For a few months in early 2021, India positioned itself as the world’s vaccine supplier of choice, before a devastating domestic wave forced a sharp reversal. This article covers what Vaccine Maitri actually delivered, why it was paused, and the criticism the programme drew on both sides of that decision.

What Vaccine Maitri Was

Vaccine Maitri, meaning “vaccine friendship,” was a diplomatic and humanitarian programme the Indian government launched on January 20, 2021, to supply and, in many cases, donate COVID-19 vaccines to other countries, drawing on India’s substantial domestic vaccine manufacturing capacity, particularly the Serum Institute of India’s production of the Covishield vaccine alongside Bharat Biotech’s domestically developed Covaxin.

The Scale of What Was Delivered

By June 2023, India had supplied approximately 301.2 million vaccine doses to 101 countries, according to Grokipedia’s detailed account of the programme, distributed across three separate channels: 15.1 million doses given as outright grants, 234.1 million doses sold through commercial export arrangements, and a further 52 million doses distributed through the international COVAX vaccine-sharing facility. Early recipients were concentrated among India’s immediate neighbours, including Bhutan, the Maldives, Nepal, Bangladesh, Myanmar, and Sri Lanka, before the programme expanded to reach countries across Africa and Latin America.

The Abrupt April 2021 Pause

The programme’s trajectory changed sharply in April 2021, when India suspended vaccine exports almost entirely as the country was hit by a severe second COVID-19 wave, with daily reported cases exceeding 400,000 at the crisis’s peak and severe shortages of hospital beds and medical oxygen reported across multiple states. At that specific moment, India’s own vaccination coverage stood at under 2 percent of the population fully vaccinated, according to Grokipedia’s account, a strikingly low domestic coverage rate given how many doses had already been sent abroad by that point.

The Domestic Criticism This Triggered

This timing generated significant domestic political criticism. Opposition politicians and commentators specifically questioned why the government had continued exporting vaccine doses, including reportedly to Pakistan in some coverage of the period, while India’s own vaccination programme lagged so far behind, criticism that intensified sharply once the severity of India’s own second wave became fully apparent through April and May 2021.

The International Fallout

The pause had real consequences beyond India’s own borders as well. Countries that had come to depend on Indian vaccine supplies, including Bangladesh and Nepal, saw their own vaccination programmes disrupted by the sudden loss of expected shipments, a gap that, according to some analysis of the period, created an opening for competing vaccine suppliers, including China, to expand their own influence in the region during the months India’s exports were paused.

Resumption and a Later Quality Concern

Exports resumed in October 2021, once India’s domestic vaccination campaign had scaled up substantially and the second wave’s most acute phase had passed. A further complication emerged later, in 2022, when World Health Organization inspections identified manufacturing deficiencies at a Bharat Biotech facility, leading to a halt in Covaxin-specific exports independent of the earlier domestic-supply pause, a separate quality-control issue rather than a repeat of the 2021 supply crisis.

A Program That Drew Both Praise and Criticism

Vaccine Maitri has been described in different terms depending on the specific period being assessed: praised in its earliest months as a genuinely significant act of vaccine diplomacy and humanitarian outreach at a moment when wealthy nations were frequently criticised for hoarding vaccine supplies, and criticised months later for having overextended relative to India’s own domestic production ramp-up, a sequencing problem analysts have pointed to as the central design flaw in how the programme was initially scaled.

The Strategic Case Supporters Made

Supporters of the programme, including some government policy analysts, have argued that even accounting for the painful April 2021 pause, the initial export push delivered real, lasting strategic value for India, strengthening its standing as a credible global health partner and specifically countering, in the assessment of analysts writing for India Foundation’s Chintan platform, the narrative that India acted purely out of self-interest during the pandemic, a reputational and diplomatic benefit they argue outlasted the temporary supply disruption the pause caused for recipient countries.

Where India’s Global Vaccine Role Stands Now

In the years since the 2021 disruption, India’s vaccine manufacturing sector has continued to play a significant role in global supply chains beyond the specific Vaccine Maitri programme itself, with the country’s status as one of the world’s largest vaccine producers by volume remaining a structural feature of global public health supply chains independent of any single diplomatic initiative, even as the specific “vaccine friendship” branding and framing associated with the 2021 programme has receded from the same level of prominence it held during the pandemic’s most acute international phase.

Bottom Line

Vaccine Maitri delivered a genuinely large volume of vaccines to a genuinely large number of countries in a short window, a significant act of global vaccine diplomacy that ran directly into the limits of India’s own production capacity when a severe domestic wave forced an abrupt April 2021 pause, disrupting recipient countries’ own programmes and drawing sustained criticism over the sequencing of exports relative to India’s own vaccination needs.

FAQ

Abhyudaya Verma